immunomodulation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
==== Ethyl carbamate ==== Urethane (ethyl carbamate) was once produced commercially in the United States as a chemotherapy agent and for other medicinal purposes. It was found to be toxic and largely ineffective. It is occasionally used in veterinary medicine in combination with other drugs to produce anesthesia.
== MP for Glasgow Hillhead and Kelvin (1987–2005) == At the 1987 general election, Galloway was elected as the MP for Glasgow Hillhead gaining the seat for Labour from the SDP defeating Roy Jenkins with a majority of 3,251 votes. Although known for his left-wing political views, Galloway was never a member of the Campaign Group.
=== Pollution and phytoremediation === EcM fungi have been found to have beneficial effects in several types of polluted environments, including: • High salt: A number of studies have shown that certain EcM fungi can help their hosts survive high soil salinity conditions. • Radionuclides: Many species of ectomycorrhizal fungi, including the Cortinariaceae, can hyperaccumulate radionuclides • Organic pollutants: Some EcM species are capable of decomposing persistent organic pollutants (POPs) such as organochlorides and polychlorinated biphenyls (PCBs). Chemicals that can be detoxified by EcM fungi, either alone or in association with their host plant, include 2,4-dichlorophenol and tetrachloroethylene.
== Medical uses == Dofetilide is used for the maintenance of sinus rhythm in individuals prone to the occurrence of atrial fibrillation and flutter arrhythmias, and for chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. Based on the results of the Danish Investigations of Arrhythmias and Mortality on Dofetilide ("DIAMOND") study, dofetilide does not affect mortality in the treatment of patients post-myocardial infarction with left ventricular dysfunction, however it was shown to decrease all-cause readmissions as well as CHF-related readmissions. Because of the results of the DIAMOND study, some physicians use dofetilide in the suppression of atrial fibrillation in individuals with LV dysfunction, however use appears limited: After initially receiving marketing approval in Europe in 1999, Pfizer voluntarily withdrew this approval in 2004 for commercial reasons and it is not registered in other first world countries. It has clinical advantages over other class III antiarrhythmics in chemical cardioversion of atrial fibrillation, and maintenance of sinus rhythm, and does not have the pulmonary or hepatotoxicity of amiodarone, however atrial fibrillation is not generally considered life-threatening, and dofetilide causes an increased rate of potentially life-threatening arrhythmias in comparison to other therapies.
GABA-T is Enzyme Commission number 2.6.1.19. This means that it is in the transferase class of enzymes, the nitrogenous transferase sub-class and the transaminase sub-subclass. As a nitrogenous transferase, its role is to transfer nitrogenous groups from one molecule to another. As a transaminase, GABA-T's role is to move functional groups from an amino acid and a α-keto acid, and vice versa. In the case of GABA-T, it takes a nitrogen group from GABA and uses it to create L-glutamate. In animals, fungi, and bacteria, GABA-T helps facilitate a reaction that moves an amine group from GABA to α-ketoglutaric acid, and a ketone group from α-ketoglutaric acid to GABA. This produces succinate semialdehyde and L-glutamic acid. In plants, pyruvic acid and glyoxylic acid can be used in the place of α-ketoglutaric acid, catalyzed by the enzyme 4-aminobutyrate—pyruvate transaminase:
Sources: en.wikipedia.org
Cell division is essential for an organism to grow, but, when a cell divides, it must replicate the DNA in its genome so that the two daughter cells have the same genetic information as their parent. The double-stranded structure of DNA provides a simple mechanism for DNA replication. Here, the two strands are separated and then each strand's complementary DNA sequence is recreated by an enzyme called DNA polymerase. This enzyme makes the complementary strand by finding the correct base through complementary base pairing and bonding it onto the original strand. As DNA polymerases can only extend a DNA strand in a 5′ to 3′ direction, different mechanisms are used to copy the antiparallel strands of the double helix. In this way, the base on the old strand dictates which base appears on the new strand, and the cell ends up with a perfect copy of its DNA.
The CAMP test (Christie–Atkins–Munch-Petersen) is a test to identify group B β-hemolytic streptococci (Streptococcus agalactiae) based on their formation of a substance, CAMP factor, that enlarges the area of hemolysis formed by the β-hemolysin elaborated from Staphylococcus aureus. Although the test is usually used to identify group B streptococcus, there is some evidence that the CAMP factor gene is present in several groups of streptococci, including group A. CAMP factor is a phospholipase produced by Group B Streptococci (Streptococcus agalactiae) that enhances hemolysis of Staphylococcus aureus. A similar factor has been identified in Bartonella henselae. The CAMP test can be used to identify Streptococcus agalactiae. Though not strongly beta-hemolytic on its own, group B strep presents with wedge-shaped colonies in the presence of Staphylococcus aureus. It can also be used to identify Listeria monocytogenes which produces a positive CAMP reaction.
Romanowsky discovered that instead of fresh methylene blue, an aged and mouldy solution gave the best result, while eosin should be free of any contamination. He described:For staining [blood sample having malarial infection] the following mixture is used, as discovered by me, which is best when freshly prepared: 2 volumes of a filtered saturated aqueous solution of methylene blue plus 5 volumes of a 1% aqueous eosin solution... In my preparations I always obtain the following picture. Red cells are stained in a pink color. Cytoplasm in eosinophils is saturated-pink, whilst that in the malaria parasite and lymphocytes is light blue. Blood platelets and the nuclei of white cell are dark-violet, whilst the nuclei of malaria parasites are purple-violet. The cytoplasm of leukocytes is pale-violet, with transitional colors between the light blue protoplasm of lymphocytes to violet leukocytes. Within red cells the malaria parasite may be hardly noticeable or may occupy the whole cell. In any event, the violet nucleus, surrounded by a colorless rim, is always clearly distinguishable.Romanowsky gave an elaborate description of the new technique in his thesis submitted in June 1891. The staining method remains the "gold standard" for visualising blood samples, especially for malarial infection, and in immunohistochemical studies.
89. Mymensingh Med J. 2026 Oct;35(4):1312-1316. Diagnosis of Rhinoentomophthoromycosis in a 55 Years Old Male: A Case Report. Shawrave SA(1), Zoheb SJM, Galib GI, Tanni RZ, Shawon MMR, Bhuiyan MJT. Author information: (1)Dr Shaharior Arafat Shawrave, Associate Professor, Department of ENT and Head Neck Surgery, Dhaka Medical College (DMC), Dhaka, Bangladesh; E-mail: shawrave77@gmail.com. Entomophthoromycosis is a chronic fungal infection characterized by a diverse range of manifestations, including subcutaneous, mucocutaneous and visceral infections. The majority of subcutaneous infections caused by entomophthoralean fungi are attributed to Basidiobolus spp, C. coronatus or C. incongruous. In this report, we present a case of rhinoentomophthoromycosis in a middle-aged, immunocompetent male, primarily affecting the nasopharynx. Initially, the diagnosis posed a dilemma, but it was ultimately confirmed through meticulous examination of microscopy and histopathology of the aspirate. The patient's response to antifungal therapy was favorable. We hereby provide a comprehensive account of this case and discuss the efficacy of Posaconazole in the treatment of rhinoentomophthoromycosis in a 55-year-old male patient with diabetes.
PmF3 + 3 Li → Pm + 3 LiF The promethium sample produced was used to measure a few of the metal's properties, such as its melting point. In 1963, ion-exchange methods were used at ORNL to prepare about ten grams of promethium from nuclear reactor fuel processing wastes. Promethium can be either recovered from the byproducts of uranium fission or produced by bombarding 146Nd with neutrons, turning it into 147Nd, which decays into 147Pm through beta decay with a half-life of 11 days.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.